TORQUE’S DAPSIMET 500

Torque’s Dapsimet 500 Tablets contains Dapagliflozin is a highly potent, selective and reversible inhibitor of SGLT2, Sitagliptin, a potent and highly selective inhibitor of the enzyme DPP-4 and Metformin, a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose.

Categories: ,

Product Description

Description: Torque’s Dapsimet 500 Tablets contains Dapagliflozin is a highly potent, selective and reversible inhibitor of SGLT2, Sitagliptin, a potent and highly selective inhibitor of the enzyme DPP-4 and Metformin, a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose.

Pharmaceutical Dosage Form: Tablet

Route of Administration: Oral

Composition:

Each film coated bilayered tablet contains:

Dapagliflozin Propanediol USP

Eq. to Dapagliflozin                                    10 mg

Sitagliptin Phosphate Monohydrate IP

Eq. to Sitagliptin                                         100 mg

Metformin Hydrochloride IP

(As extended release form)                          500 mg

Excipients                                                   q.s.

Mechanism of Action: Dapagliflozin inhibits SGLT2 thus reduces reabsorption of glucose from the glomerular filtrate in the proximal renal tubule with a concomitant reduction in sodium reabsorption leading to urinary excretion of glucose and osmotic diuresis. Dapagliflozin improves both fasting and post-prandial plasma glucose levels. Sitagliptin by inhibiting the DPP-4 enzyme, increases the levels of two known active incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.

Indications: Torque’s Dapsimet 500 is indicated for the treatment of patients with type II diabetes mellitus when diet, exercise and single agent does not result in adequate glycemic control.

Dosage: As directed by the physician.

Storage: Store protected from light & moisture, at a temperature not exceeding 30°C.

Presentation: 10 x 15

Side effects: The following adverse reactions may occur:

Lactic Acidosis

Taste Disturbance

Loss of Appetite

Hypoglycaemia

Flatulence

Nausea

Vomiting

Constipation

Diarrhoea

Abdominal Pain

Peripheral Oedema

Headache

Dizziness

Contraindications:

Torque’s Dapsimet 500 is contraindicated in patients with:

Known hypersensitivity to metformin or any of the components of this product.

any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis)

diabetic pre-coma

Severe renal impairment

Acute conditions with the potential to alter renal function such as:

– dehydration,

– severe infection,

– shock

Disease which may cause tissue hypoxia

Decompensated Heart Failure

Respiratory Failure

Recent Myocardial Infarction

Shock

Hepatic insufficiency, acute alcohol intoxication, alcoholism

Drug Interactions:

Alcohol

NSAIDs

ACE Inhibitors

Angiotensin II Receptor Antagonists

Diuretics

Verapamil

Rifampicin

Cimetidine, Ranolazine, Trimethoprime

Isavuconazole, ketoconazole, itraconazole

Vandetanib, Crizotinib, Olaparib

ritonavir, Dolutegravir, clarithromycin

Ciclosporin

Digoxin